Nelson Vergel
Founder, ExcelMale.com
FDA approval of Tlando follows in the footsteps of Jatenzo
The recommended dosage is 225 mg orally twice daily with food. It does not require dose titration.
"We believe Tlando's oral formulation and convenient dosing, which requires no titration, differentiates it from other treatment options," noted Apple.
The drug was also deemed a Schedule III controlled substance, due to risks of abuse and misuse of testosterone.
Tlando joins an already lengthy list of testosterone treatments, the vast majority of which are injectable or topical. This approval most closely follows the 2019 approval of Clarus Therapeutics' own version of oral testosterone undecanoate marketed under the trade name Jatenzo.